

Press Release

Within the Scope of the „BioChancePlus“ Competition, MediGene Receives a Research Grant of Approx. 600,000 Euros from the Federal Ministry of Education and Research

Martinsried/Munich, February 11, 2008. Within the scope of the funding program "KMU-innovativ: Biotechnologie - BioChance" MediGene AG (Frankfurt, Prime Standard: MDG) will receive a research grant totaling approximately 600,000 Euros, paid by the Federal Ministry of Education and Research (BMBF = Bundesministerium für Bildung und Forschung) over a period of three years.

The „BioChancePlus“ competition shall boost the innovation potential of small and medium-sized enterprises in the field of top-level research. Another purpose of the funding program is to strengthen the technological foundation of biotech companies in order to provide a basis for their sustained growth. MediGene's research activities in the field of immunology fulfill the criteria „excellence“, „innovation level“, and „significance of the company's contribution to resolving current socially relevant problems“, and will therefore be funded.

Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, comments: „We are proud that our research project was chosen for this renowned funding program by an independent academic committee. This underlines our company's expertise in research. Government funding of innovative research and development activities is a very important and positive signal for the biotech site Germany.“

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGene™ is a trademark of MediGene AG.

- ends -

MediGene AG is a publicly quoted (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market. In 2008, the company plans to start its own sales activities in select European countries. MediGene's drug pipeline includes several products in clinical development, among them two drug candidates with an estimated revenue potential of more than one billion Euro. In addition, MediGene is active in various research projects and possesses platform technologies for developing active compounds.

Contact MediGene AG:

Julia Hofmann/Dr. Georg Dönges, Public Relations
Dr. Michael Nettersheim, Investor Relations

Email: investor@medigene.com

Fax: ++49 - 89 - 85 65 - 2920

Tel.: ++49 - 89 - 85 65 - 3317

Tel.: ++49 - 89 - 85 65 - 2946